QT Imaging’s Breast Acoustic CT™ Scanner Used in Study for Early Identification of Response of Breast Cancer Patients to Neoadjuvant Chemotherapy
14 March 2024 - 11:30PM
Business Wire
QT Imaging Holdings, Inc. (NASDAQ:QTI) a medical device company
engaged in research, development, and commercialization of
innovative body imaging systems, is pleased to announce the
delivery of a Breast Acoustic CT™ Scanner under a unique
collaboration with the Department of Radiation Oncology, and
Radiation Treatment Program at the Sunnybrook Health Sciences
Centre in Toronto, Canada, one of the largest cancer centers in
Canada, and The University of Illinois, Urbana-Champaign,
Department of Electrical and Computer Engineering and Grainger
College of Engineering. This collaboration is part of a five-year
research grant from National Institutes of Health/National Cancer
Institute to develop an inexpensive, portable, safe, and repeatable
imaging approach capable of accurate and early identification of
response of breast cancer patients to neoadjuvant chemotherapy
(NAC).
As part of this grant, Breast Acoustic CT™ (ACT) quantitative
images with independent biomarkers known to be sensitive to cancer
will be collected, and the response of cancer to therapy, will be
derived from quantitative ultrasound based on backscatter analysis.
The successful results of this collaboration will yield additional
quantitative markers (radiomics) with improved estimate precision
not afforded by conventional ultrasound scanners.
This collaboration also addresses the ongoing clinical need in
breast cancer therapy for the development of an inexpensive,
robust, and accurate technique to identify the response, within
weeks, of breast cancer to neoadjuvant chemotherapy. The early
identification of non-responders to NAC or any cancer treatment
remains a highly significant medical problem and necessary for
adaptive precision medicine.
"The QTI Breast Acoustic CT™ System represents the future of
tomographic imaging, offering quantitatively accurate, 3D, high
resolution breast images, taken with no safety or discomfort for
women," said James Wiskin, PhD, Principal Scientist and QTI Fellow.
"The ACT system is especially appropriate for dense breasts and
young women with risk factors. This partnership serves as a
testament to collaborations between leaders in industry and
academia."
"Unfortunately, not all therapies work in cancer patients and
the ability to determine which are effective and which treatments
are ineffective in days instead of months is very important. With
the QTI Breast Acoustic CT™ System we plan to implement
quantitative ultrasound methods which can be used for exactly that
kind of determination to enable personalized care," stated Greg
Czarnota, MD, PhD, Clinician Scientist Department of Radiation
Oncology at Sunnybrook Health Sciences Centre in Toronto,
Canada.
About QT Imaging Holdings, Inc.
QT Imaging Holdings, Inc. is a public (NASDAQ: QTI) medical
device company engaged in research, development, and
commercialization of innovative body imaging systems using low
frequency sound waves. QT Imaging Holdings, Inc. strives to improve
global health outcomes. Its strategy is predicated upon the fact
that medical imaging is critical to the detection, diagnosis, and
treatment of disease and that it should be safe, affordable,
accessible, and centered on the patient’s experience. For more
information on QT Imaging Holdings, Inc., please visit the
company’s website at www.qtimaging.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Such statements contain words such as “will,” and
“expect,” or the negative thereof or comparable terminology, and
include (without limitation) statements regarding the QTI Breast
Acoustic CT™ System and its use in the research collaboration and
images that may be rendered as part of this research, plans for QT
Imaging Holdings, new product development and introduction, and
product sales growth and projected revenues. Forward-looking
statements involve certain risks and uncertainties, and actual
results may differ materially from those discussed in any such
statement. These risks include, but are not limited to: the ability
of the parties to sell and deploy the QTI Breast Acoustic CT™
System, the ability to extend product offerings into new areas or
products, the ability to commercialize technology, unexpected
occurrences that deter the full documentation and “bring to market”
plan for products, trends and fluctuations in the industry, changes
in demand and purchasing volume of customers, unpredictability of
suppliers, the ability to attract and retain qualified personnel
and the ability to move product sales to production levels.
Additional factors that could cause actual results to differ are
discussed under the heading “Risk Factors” and in other sections of
QT Imaging’s (and its predecessor, GigCapital5, Inc.) filings with
the SEC, and in its other current and periodic reports filed or
furnished from time to time with the SEC. All forward-looking
statements in this press release are made as of the date hereof,
based on information available to QT Imaging Holdings as of the
date hereof, and QT Imaging Holdings assumes no obligation to
update any forward-looking statement.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240314628313/en/
Stas Budagov Chief Financial Officer
Stas.Budagov@qtimaging.com
QT Imaging (NASDAQ:QTI)
Historical Stock Chart
From Apr 2024 to May 2024
QT Imaging (NASDAQ:QTI)
Historical Stock Chart
From May 2023 to May 2024